创新是值得的价格吗? 干预瘤学的成本效益分析
Ludovico Cavallaro1, Carla Rognoni2
1Center for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Via Sarfatti, 10, 20136, Milan (MI), Italy. ludovico.cavallaro@unibocconi.it.
成本效益分析 (CEA) 通过评估干预价值来指导医疗保健资源的分配. 本研究表明CEA如何支持干预瘤学的基于证据的政策,平衡成本和临床效益.
科学领域:
- 卫生经济学 卫生经济学
- 医疗技术评估 (HTA) 是指对医疗技术进行评估.
背景情况:
- 成本效益分析 (CEA) 对医疗保健决策和资源分配至关重要.
- 严格的CEA涉及选择比较器,评估成本,评估结果,并使用可靠的建模.
- 干预瘤学面临的挑战是创新的,昂贵的程序,需要证明长期益处.
研究的目的:
- 为了说明CEA如何支持基于证据的医疗保健政策.
- 为了证明CEA在干预瘤学的应用.
主要方法:
- 使用Rognoni等人的一项案例研究.
- 对比跨动脉放射栓塞 (TARE) 和索拉费尼布用于肝脏瘤.
- 应用综合性成本评估和结果评估的原则.
主要成果:
- CEA提供了经济证据,以平衡临床有效性和资源效率.
- CEA的调查结果为医疗干预的金钱价值评估提供了信息.
- 该案例研究强调了CEA在指导肝脏瘤治疗的医疗保健政策方面的作用.
结论:
- 在HTA中,CEA对于明智的医疗保健决策至关重要.
- 来自CEA的经济证据对于采用创新的瘤治疗方法至关重要.
- 在更广泛的HTA框架内,CEA支持高效和道德的资源分配.
更多相关视频
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
08:17Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Cancer Survival Analysis
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Comparing the Survival Analysis of Two or More Groups
Hazard Ratio
For example, in a clinical trial...
Targeted Cancer Therapies
There are several types of targeted therapies against...
